Information contained on this page is provided by an independent third-party content provider. WorldNow and this Station make no warranties or representations in connection therewith. If you have any questions or comments about this page please contact firstname.lastname@example.org.
SOURCE Bernstein Liebhard LLP
NEW YORK, Dec. 12, 2013 /PRNewswire/ -- Byetta lawsuits (http://www.byettalawsuit2013.com/) and other product liability claims involving a class of Type 2 diabetes drugs called incretin mimetics continue to move forward in a multidistrict litigation now underway in U.S. District Court, Southern District of California, Bernstein Liebhard LLP reports. According to an Order dated December 2nd, the Court has approved the use of a Master Complaint and Short Form Complaint for all cases filed in the litigation. All of the lawsuits pending in the proceeding involve similar allegations that Byetta, as well as Januvia, Janumet and Victoza, can increase a patient's risk of developing pancreatic cancer. (In Re: Incretins Products Liability, Sales and Marketing Litigation, MDL 2452)
"Our Firm has heard from numerous individuals concerned about the association between Byetta and pancreatic cancer. The adoption of the Master and Short Form Complaints will do much to streamline the process for filing a Byetta lawsuit," says Bernstein Liebhard LLP, a nationwide law firm representing victims of defective drugs and medical devices. The Firm is currently offering free Byetta lawsuit reviews to patients who took this medication and were diagnosed with pancreatic cancer, thyroid cancer or pancreatitis.
Byetta Pancreatic Cancer Allegations
Byetta and other incretin mimetics, including Januvia, Janumet and Victoza, mimic the action of incretin hormones in the intestinal track to stimulate the pancreas to produce insulin. The U.S. Food & Drug Administration (FDA) announced in March that it was investigating a possible connection between incretin mimetics like Byetta and pancreatic cancer. The review was prompted by the findings from an unpublished study that indicated this class of Type 2 diabetes medications could cause precancerous changes in the cells of the pancreas. The FDA has since noted that it was unable to reach any conclusion regarding this possible risk, but its review is ongoing.
A month after the FDA announced its review, the Institute for Safe Medicine Practices published the results of an analysis that showed the FDA's Adverse Event Reporting Database had received 263 reports of Byetta pancreatitis, 71 cases of Byetta pancreatic cancer, and 14 incidents of Byetta thyroid cancer in a single 12-month period. That study was followed by the June publication of a British Medical Journal investigation that found the manufacturers of Byetta and other incretin mimetics may have downplayed the drugs' potential to harm the pancreas.
According to court documents, at least 150 lawsuits involving Byetta and other incretin mimetics have been filed in the multidistrict litigation underway in the Southern District of California. All of the Byetta lawsuits pending in the proceeding allege that the manufacturer of the drug failed to warn doctors and patients about its dangerous pancreatic side effects.
Patients who have used Byetta and who went on to develop pancreatic cancer, pancreatitis, or thyroid cancer may be entitled to compensation for their injury-related damages. To learn more about filing a Byetta lawsuit, please visit Bernstein Liebhard LLP's website, or call one of the Firm's attorneys today for a free case review at (888) 340-4807.
About Bernstein Liebhard LLP
Bernstein Liebhard LLP is a New York-based law firm exclusively representing injured persons in complex individual and class action lawsuits nationwide since 1993, including those who have been harmed by dangerous drugs, defective medical devices and consumer products. The firm has been named by The National Law Journal to the "Plaintiffs' Hot List," recognizing the top plaintiffs' firms in the country, for the past 11 consecutive years.
Bernstein Liebhard LLP
10 East 40th Street
New York, New York 10016
ATTORNEY ADVERTISING. © 2013 Bernstein Liebhard LLP. The law firm responsible for this advertisement is Bernstein Liebhard LLP, 10 East 40th Street, New York, New York 10016, (888) 340-4807. Prior results do not guarantee or predict a similar outcome with respect to any future matter.
Felecia L. Stern, Esq.
Bernstein Liebhard LLP
info (at) consumerinjurylawyers (dot) com
©2012 PR Newswire. All Rights Reserved.